Carbamoylphosphonates, a New Class of in Vivo Active Matrix Metalloproteinase Inhibitors. 1. Alkyl- and Cycloalkylcarbamoylphosphonic Acids
- 16 April 2004
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (11) , 2826-2832
- https://doi.org/10.1021/jm030386z
Abstract
Matrix metalloproteinases (MMPs) are a family of over 20 zinc-dependent enzymes that hydrolyze connective tissue and are involved in a variety of diseases, which are associated with undesired tissue breakdown. This paper reports the synthesis, characterization, and biological evaluation of a novel class of MMP inhibitors based on the carbamoylphosphonic acid function. We report a series of 10 open chain N-alkylcarbamoylphosphonic acids (ranging from R = C1 to C6 groups), eight N-cycloalkylcarbamoylphosphonic acids (ranging from cyclopropyl to cyclooctyl rings), and four N,N-dialkylcarbamoylphosphonic acids. The compounds were evaluated in three in vitro models, which consisted of (a) the in vitro invasion across a reconstituted basement membrane, (b) determination of the IC50 values on recombinant MMP-1, MMP-2 MMP-3, MMP-8, and MMP-9 enzymes, and (c) an in vitro capillary formation model, which is a model of angiogenesis. Several of the compounds were also tested in an in vivo murine melanoma model. The following general conclusions have been reached: Most compounds show selectivity for MMP-2 over the other MMP subtypes examined. Cycloalkylcarbamoylphosphonic acids are more potent than comparable open-chain alkyl compounds. Optimal activity against MMP-2 among the cycloalkyl derivatives was shown by N-cyclopentylcarbamoylphosphonic acid (3m). N,N-Dialkylcarbamoylphosphonic acids that were examined showed weak or no activity. The compounds examined showed toxic effects neither in vitro nor in vivo in the concentrations used. Carbamoylphosphonic acids are water soluble at physiological pH and are stable indefinitely.Keywords
This publication has 21 references indexed in Scilit:
- Crystal Structure of Human MMP9 in Complex with a Reverse Hydroxamate InhibitorJournal of Molecular Biology, 2002
- Development of Matrix Metalloproteinase Inhibitors in Cancer TherapyJNCI Journal of the National Cancer Institute, 2001
- Solid Phase Combinatorial Library of Phosphinic Peptides for Discovery of Matrix Metalloproteinase InhibitorsJournal of Combinatorial Chemistry, 2000
- Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenaseArthritis & Rheumatism, 2000
- Role of Matrix Metalloproteinases and Their Inhibition in Cutaneous Wound Healing and Allergic Contact HypersensitivityAnnals of the New York Academy of Sciences, 1999
- Matrix metalloproteinases and metastasisCancer Chemotherapy and Pharmacology, 1999
- Synthesis, Characterization, and Crystal Structure of Dicalcium Glutarylbis(phosphonate) Dihydrate: A Covalently Pillared Layer Structure with the Potential for Epitaxial Growth on HydroxyapatiteInorganic Chemistry, 1998
- Phosphinic acid inhibitors of matrix metalloproteinasesBioorganic & Medicinal Chemistry Letters, 1996
- Potent and selective inhibitors of gelatinase-A 2. carboxylic and phosphonic acid derivativesBioorganic & Medicinal Chemistry Letters, 1994
- Structure of the Catalytic Domain of Fibroblast Collagenase Complexed with an InhibitorScience, 1994